CTIC - CTI BioPharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.89
+0.01 (+0.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.88
Open3.88
Bid3.76 x 1000
Ask4.16 x 1500
Day's Range3.82 - 3.90
52 Week Range2.45 - 4.52
Volume69,054
Avg. Volume427,222
Market Cap225.546M
Beta-0.23
PE Ratio (TTM)N/A
EPS (TTM)-1.24
Earnings DateFeb 28, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
Trade prices are not sourced from all markets
  • What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?
    Simply Wall St.3 days ago

    What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?

    The latest earnings announcement CTI BioPharma Corp’s (NASDAQ:CTIC) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...

  • ACCESSWIRElast month

    Wired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology

    Stock Monitor: Fate Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on CTI BioPharma Corp. (NASDAQ: CTIC ). ...

  • CTI BioPharma to Present at Upcoming Investor Conferences
    PR Newswirelast month

    CTI BioPharma to Present at Upcoming Investor Conferences

    SEATTLE , March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences ...

  • CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
    PR Newswirelast month

    CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology

    SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy (BAT), which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis and thrombocytopenia (defined as platelet counts ≤100 x 109/L). In the intent-to-treat patient population of the study, the combined pacritinib arms (400mg once daily and 200mg twice daily dosing, 149 patients total) demonstrated a significant improvement of 35% or more in spleen volume reduction (SVR) at 24 weeks of treatment in 27 patients (18%) compared to 2 patients (3%) out of 72 patients in the BAT arm, which included treatment with ruxolitinib (P=0.001).

  • Associated Presslast month

    CTI BioPharma reports 4Q loss

    The Seattle-based company said it had a loss of 33 cents per share. Losses, adjusted for stock option expense, came to 30 cents per share. The biotechnology company posted revenue of $462,000 in the period. ...

  • CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results
    PR Newswirelast month

    CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results

    -Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern Time- SEATTLE , March 7, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the fourth quarter ...

  • CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio?
    Simply Wall St.last month

    CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio?

    If you are a shareholder in CTI BioPharma Corp’s (NASDAQ:CTIC), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • ACCESSWIRElast month

    CTI BioPharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / CTI BioPharma Corp. (NASDAQ: CTIC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern Time. ...

  • When Will CTI BioPharma Corp (NASDAQ:CTIC) Breakeven?
    Simply Wall St.2 months ago

    When Will CTI BioPharma Corp (NASDAQ:CTIC) Breakeven?

    CTI BioPharma Corp’s (NASDAQ:CTIC): CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.Read More...

  • CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
    PR Newswire2 months ago

    CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018

    SEATTLE , Feb. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2017 financial results on Wednesday, ...

  • CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
    PR Newswire2 months ago

    CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference

    SEATTLE , Feb. 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the 7 th Annual Leerink Partners Global Healthcare Conference ...

  • CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
    PR Newswire2 months ago

    CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock

    SEATTLE, Feb. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. ("CTI BioPharma") (CTIC) today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, the underwriters exercised in full their option to purchase 3,000,000 additional shares of common stock at the public offering price, less the underwriting discount. The expected proceeds to CTI BioPharma from the offering are approximately $64.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by CTI BioPharma.

  • CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
    PR Newswire2 months ago

    CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock

    SEATTLE, Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPharma has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less the underwriting discount. Proceeds to CTI BioPharma from the offering are expected to be $55.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by CTI BioPharma.

  • CTI BioPharma Announces Launch of Follow-On Offering
    PR Newswire2 months ago

    CTI BioPharma Announces Launch of Follow-On Offering

    SEATTLE, Feb. 5, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced the launch of a proposed underwritten public offering of shares of its common stock. In addition, CTI BioPharma expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The Company intends to use the net proceeds of the offering to complete the PAC203 clinical trial, complete the review of the pacritinib MAA by the EMA, conduct additional research concerning the possible application of pacritinib in indications outside of myelofibrosis, and complete the PIX306 clinical trial, as well as for general corporate purposes, which may include funding research and development, conducting preclinical and clinical trials, acquiring or in-licensing potential new pipeline candidates, preparing and filing possible new drug applications and general working capital.

  • Who Owns CTI BioPharma Corp (NASDAQ:CTIC)?
    Simply Wall St.3 months ago

    Who Owns CTI BioPharma Corp (NASDAQ:CTIC)?

    I am going to take a deep dive into CTI BioPharma Corp’s (NASDAQ:CTIC) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • CTI BioPharma Provides Corporate and European Regulatory Update
    PR Newswire3 months ago

    CTI BioPharma Provides Corporate and European Regulatory Update

    SEATTLE, Jan. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced that it has been reincorporated in the State of Delaware following a Special Meeting of Shareholders, triggering an automatic delisting of CTI's common stock from the Borsa Italiana MTA exchange. The Company also provided an update of the status of the Marketing Authorization Application of pacritinib to the European Medicines Agency (EMA).

  • How Is Novartis’s Kymriah Positioned for 2018?
    Market Realist3 months ago

    How Is Novartis’s Kymriah Positioned for 2018?

    In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.

  • CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®
    PR Newswire3 months ago

    CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®

    SEATTLE, Jan. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries Ltd.  related to the achievement of a milestone for U.S. Food and Drug Administration approval of TRISENOX® (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with Teva under which CTI BioPharma is eligible to receive up to an additional $50 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.

  • What Are Analysts Saying About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trend?
    Simply Wall St.3 months ago

    What Are Analysts Saying About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trend?

    In September 2017, CTI BioPharma Corp (NASDAQ:CTIC) released its most recent earnings announcement, which confirmed that losses became smaller relative to the prrior year’s level as a result of recentRead More...

  • Capital Cube4 months ago

    ETFs with exposure to CTI BioPharma Corp. : January 1, 2018

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
    Capital Cube4 months ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of CTI BioPharma Corp. – Madrigal Pharmaceuticals, Inc., Celgene Corporation, Amgen Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Limited Sponsored ADR, Incyte Corporation, Eli Lilly and Company, Baxter International ... Read more (Read more...)

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMT

    Q3 2017 CTi Biopharma Corp Earnings Call

  • Does CTI BioPharma Corp’s (NASDAQ:CTIC) Past Performance Indicate A Stronger Future?
    Simply Wall St.4 months ago

    Does CTI BioPharma Corp’s (NASDAQ:CTIC) Past Performance Indicate A Stronger Future?

    Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess CTI BioPharma Corp’s (NASDAQ:CTIC) track record on aRead More...

  • Is CTI BioPharma Corp (CTIC) Undervalued?
    Simply Wall St.5 months ago

    Is CTI BioPharma Corp (CTIC) Undervalued?

    CTI BioPharma Corp (NASDAQ:CTIC), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Capital Cube5 months ago

    ETFs with exposure to CTI BioPharma Corp. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)